Nemvaleukin and Pembrolizumab Combination + Pembrolizumab + Nemvaleukin + Pegylated Liposomal Doxorubicin (PLD) + Paclitaxel + Topotecan + Gemcitabine
Phase 3Terminated 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Platinum-resistant Ovarian Cancer
Conditions
Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Trial Timeline
Jan 10, 2022 → May 8, 2025
NCT ID
NCT05092360About Nemvaleukin and Pembrolizumab Combination + Pembrolizumab + Nemvaleukin + Pegylated Liposomal Doxorubicin (PLD) + Paclitaxel + Topotecan + Gemcitabine
Nemvaleukin and Pembrolizumab Combination + Pembrolizumab + Nemvaleukin + Pegylated Liposomal Doxorubicin (PLD) + Paclitaxel + Topotecan + Gemcitabine is a phase 3 stage product being developed by Merck for Platinum-resistant Ovarian Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT05092360. Target conditions include Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05092360 | Phase 3 | Terminated |
Competing Products
16 competing products in Platinum-resistant Ovarian Cancer